Michael Hill
DPhil
Laboratory Scientific Director
Associate Professor Mike Hill joined CTSU in 2009 and is the Laboratory Scientific Director of the NDPH Wolfson Laboratories. He has a background in population-based studies and functional studies associated with respiratory and cardiovascular disease. He manages a team of 40 research and technical staff and is responsible for senior strategic oversight of all aspects of laboratory research within NDPH.
Mike works closely with NDPH’s principal investigators, providing central laboratory support for their clinical trials and observational studies ensuring the scientific integrity of the laboratory work.
Research interests include investigating new biochemical markers and validating analytical methods suitable for large-scale research. NDPH Wolfson Laboratories are a UKAS accredited testing laboratory (ISO 17025:2017 No. 2799) with extensive computer automation and a particular expertise in developing reliable high-throughput methods of analysis in clinical chemistry and protein biomarkers.
Previous history: Mike gained his DPhil at the University of Oxford in 1992 and continued his post-doctoral studies at the Nuffield Department of Clinical Medicine, Oxford and The Wellcome Trust Centre for Human Genetics, Oxford. In 1998, he joined the Division of Medicine at University College London where he led a research group.
Recent publications
-
Proteomic Analyses in Diverse Populations Improved Risk Prediction and Identified New Drug Targets for Type 2 Diabetes.
Journal article
Yao P. et al, (2024), Diabetes Care
-
Infectious pathogens and risk of esophageal, gastric and duodenal cancers and ulcers in China: A case-cohort study.
Journal article
Kartsonaki C. et al, (2024), Int J Cancer, 154, 1423 - 1432
-
Author Correction: Genotyping, sequencing and analysis of 140,000 adults from Mexico City.
Journal article
Ziyatdinov A. et al, (2024), Nature, 626
-
Genome-wide SNP-sex interaction analysis of susceptibility to idiopathic pulmonary fibrosis.
Journal article
Leavy OC. et al, (2024), medRxiv
-
A common NFKB1 variant detected through antibody analysis in UK Biobank predicts risk of infection and allergy.
Journal article
Chong AY. et al, (2024), Am J Hum Genet